
    the study was terminated early based on the results of the planned interim analysis.
  
['pancreatic cancer']
['ruxolitinib', 'placebo', 'capecitabine']

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas.

          -  Advanced adenocarcinoma of the pancreas that is inoperable or metastatic.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

          -  Received 1 prior chemotherapy regimen for advanced or metastatic disease (not
             including neoadjuvant and/or adjuvant therapy).

          -  ≥ 2 weeks elapsed from the completion of previous treatment regimen and participants
             must have recovered or be at a new stable baseline from any related toxicities.

          -  Radiographically measurable or evaluable disease

          -  Modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:

               1. mGPS of 1: C-reactive protein >10 mg/L and albumin ≥35 g/L

               2. mGPS of 2: C-reactive protein >10 mg/L and albumin <35 g/L

        Exclusion Criteria:

          -  Received more than 1 prior regimen for advanced or metastatic disease.

          -  Ongoing radiation therapy, radiation therapy administered within 30 days of
             enrollment.

          -  Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery,
             immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor
             embolization).

          -  Prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase
             deficiency (DPD), or other known hypersensitivity to active substances, including
             fluorouracil (5-FU), or ruxolitinib, or any of their excipients.

          -  Prior treatment with a JAK inhibitor for any indication.
      